

# CITATION REPORT

List of articles citing

## Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure Prophylaxis

DOI: 10.1177/135965350400900115  
Antiviral Therapy, 2004, 9, 57-65.

**Source:** <https://exaly.com/paper-pdf/145591506/citation-report.pdf>

**Version:** 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
175	High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. <b>2004</b> , 74, 197-201		52
174	Antiviral drugs in current clinical use. <b>2004</b> , 30, 115-33		758
173	Natural resistance of human immunodeficiency virus type 2 to zidovudine. <i>Virology</i> , <b>2005</b> , 336, 251-64	3.6	28
172	Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France. <b>2005</b> , 75, 381-90		28
171	Viral response to antiretroviral therapy in a patient coinfecting with HIV type 1 and type 2. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 41, e19-21	11.6	19
170	Enfuvirtide is active against HIV type 1 group O. <i>AIDS Research and Human Retroviruses</i> , <b>2005</b> , 21, 583-5	1.6	29
169	Duplication of peri-kappaB and NF-kappab sites of the first human immunodeficiency virus type 2 (HIV-2) transmission in Brazil. <i>AIDS Research and Human Retroviruses</i> , <b>2005</b> , 21, 965-70	1.6	7
168	[HIV entry into the cells--mechanisms and therapeutic possibilities]. <b>2006</b> , 126, 341-8		0
167	High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. <i>Aids</i> , <b>2006</b> , 20, 127-9	3.5	27
166	Failure of HIV-2 viral load assay in a severely immunodeficient patient: clinical and therapeutic management issues. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , <b>2006</b> , 100, 282-4	2	2
165	Current status of antiretroviral therapy. <b>2006</b> , 7, 1541-54		60
164	A novel colorimetric assay for CXCR4 and CCR5 tropic human immunodeficiency viruses. <b>2006</b> , 17, 215-23		8
163	A rapid and sensitive real-time PCR assay for the K65R drug resistance mutation in SIV reverse transcriptase. <i>AIDS Research and Human Retroviruses</i> , <b>2006</b> , 22, 912-6	1.6	14
162	Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?. <b>2007</b> , 8, 371-82		23
161	Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. <i>International Journal of Antimicrobial Agents</i> , <b>2007</b> , 30, 297-308	14.3	259
160	Discovery of novel non-cytotoxic salicylhydrazide containing HIV-1 integrase inhibitors. <b>2007</b> , 17, 6472-5		37
159	Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. <i>BMC Infectious Diseases</i> , <b>2008</b> , 8, 21	4	34

158	Species barrier of HIV-1 and its jumping by virus engineering. <b>2008</b> , 18, 261-75		27
157	Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. <b>2008</b> , 71, 298-305		79
156	Efavirenz--still first-line king?. <b>2008</b> , 4, 965-72		32
155	Epidemiology, Natural History and Treatment of HIV-2 Infections. <b>2008</b> , 637-647		1
154	[Antiretroviral therapy: principles for treating HIV infection]. <b>2008</b> , 37, 1022-32		2
153	HIV-2: the forgotten AIDS virus. <b>2008</b> , 16, 588-95		127
152	HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. <b>2008</b> , 29, 42-9		41
151	Atazanavir: its role in HIV treatment. <b>2008</b> , 6, 785-96		20
150	Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity. <b>2008</b> , 51, 388-91		50
149	Reassessment of enfuvirtide's role in the management of HIV-1 infection. <b>2008</b> , 9, 2349-62		9
148	Drug resistance differences among HIV types and subtypes: a growing problem. <b>2008</b> , 2, 579-593		3
147	Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2008</b> , 52, 329-32	5.9	30
146	HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 62, 914-20	5.1	101
145	Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. <i>Aids</i> , <b>2008</b> , 22, 457-68	3.5	66
144	Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. <i>Aids</i> , <b>2008</b> , 22, 665-6	3.5	45
143	Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. <i>Aids</i> , <b>2008</b> , 22, 2045-6	3.5	34
142	Occupational Exposure to Zoonotic Simian Retroviruses: Health and Safety Implications for Persons Working with Nonhuman Primates. <b>2008</b> , 251-264		
141	Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resource-limited West Africa. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 48, 476-83	11.6	68

140	Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease. <b>2009</b> , 18, 2442-53		19
139	Current and Novel Inhibitors of HIV Protease. <b>2009</b> , 1, 1209-39		83
138	Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors. <b>2009</b> , 52, 7887-91		41
137	Elvitegravir: a new HIV integrase inhibitor. <b>2009</b> , 20, 79-85		63
136	First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the leDEA West Africa collaboration. <i>Aids</i> , <b>2010</b> , 24, 1043-50	3.5	23
135	A few specialized issues that should be focused on anti-HIV drug evaluation in vitro. <b>2010</b> , 25, 301-6		2
134	Evaluation of antiretrovirals in animal models of HIV infection. <i>Antiviral Research</i> , <b>2010</b> , 85, 159-75	10.8	42
133	Baseline characteristics, response to and outcome of antiretroviral therapy among patients with HIV-1, HIV-2 and dual infection in Burkina Faso. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , <b>2010</b> , 104, 154-61	2	18
132	Evaluation of four rapid tests for diagnosis and differentiation of HIV-1 and HIV-2 infections in Guinea-Conakry, West Africa. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , <b>2010</b> , 104, 571-6	2	19
131	Towards Inhibition of Vif-APOBEC3G Interaction: Which Protein to Target?. <b>2010</b> , 2010, 649315		5
130	HIV Genetic Diversity and Drug Resistance. <b>2010</b> , 2, 503-31		35
129	Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure. <b>2010</b> , 47, 79-81		21
128	[Current situation of human immunodeficiency virus type 2 and Human T lymphotropic virus in Spain]. <b>2010</b> , 28, 442-5		3
127	HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?. <i>Clinical Drug Investigation</i> , <b>2011</b> , 31, 345-9	3.2	6
126	Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings. <b>2011</b> , 2011, 463704		31
125	HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa. <i>PLoS ONE</i> , <b>2011</b> , 6, e22204	3.7	19
124	Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients. <i>Journal of Virology</i> , <b>2011</b> , 85, 2429-38	6.6	37
123	Drug resistance mutations in patients infected with HIV-2 living in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 1484-8	5.1	26

122	Update on human immunodeficiency virus (HIV)-2 infection. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 52, 780-7	11.6	138
121	Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naïve HIV-2-infected patients: The ACHIEVE2E Collaboration Study Group. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 52, 1257-66	11.6	33
120	Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance. <i>Aids</i> , <b>2011</b> , 25, 2235-41	3.5	21
119	Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations. <b>2011</b> , 6, 295-315		14
118	A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. <b>2012</b> , 8, e1002774		63
117	The evolution of drug resistance interpretation algorithms: ANRS, REGA and extension of resistance analysis to HIV-1 group O and HIV-2. <b>2012</b> , 55, 128-33		9
116	Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool. <b>2012</b> , 205, 111-20		33
115	Baseline susceptibility of primary HIV-2 to entry inhibitors. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 565-70	1.6	37
114	Special aspects of the treatment of HIV-2-infected patients. <b>2012</b> , 55, 179-83		28
113	Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa. <b>2012</b> , 12, 95		13
112	Concise synthesis and anti-HIV activity of pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic heterocycles. <i>Organic and Biomolecular Chemistry</i> , <b>2012</b> , 10, 6792-802	3.9	22
111	Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors. <b>2012</b> , 21, 339-50		35
110	Mechanism of HIV antiretroviral drugs progress toward drug resistance. <b>2012</b> , 26, 146-61		23
109	Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy. <i>Virology</i> , <b>2012</b> , 423, 107-18	3.6	90
108	Population mobility and the changing epidemics of HIV-2 in Portugal. <i>HIV Medicine</i> , <b>2012</b> , 13, 219-25	2.7	7
107	Closing the door to human immunodeficiency virus. <b>2013</b> , 4, 86-102		13
106	Animal Models of Human Viral Diseases. <b>2013</b> , 927-970		1
105	Mutations selected in HIV-2-infected patients failing a regimen including atazanavir. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 190-2	5.1	15

104	Non-M variants of human immunodeficiency virus type 1. <b>2013</b> , 26, 448-61		46
103	Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. <i>Aids</i> , <b>2013</b> , 27, 292-5	3.5	6
102	HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 1654-8	11.6	27
101	In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 5320-9	5.9	6
100	Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 2751-60	5.9	34
99	Comprehensive in vitro analysis of simian retrovirus type 4 susceptibility to antiretroviral agents. <i>Journal of Virology</i> , <b>2013</b> , 87, 4322-9	6.6	5
98	Encyclopedia of AIDS. <b>2013</b> , 1-9		
97	Robust suppression of env-SHIV viremia in <i>Macaca nemestrina</i> by 3-drug ART is independent of timing of initiation during chronic infection. <b>2013</b> , 42, 237-46		13
96	Re-testing and misclassification of HIV-2 and HIV-1&2 dually reactive patients among the HIV-2 cohort of the West African Database to evaluate AIDS collaboration. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19064	5.4	20
95	Humanized Mouse Versus Non-human Primate Models of HIV-1 Infection. <b>2014</b> , 209-221		
94	. <b>2014</b> ,		
93	HIV-2 viral tropism influences CD4+ T cell count regardless of viral load. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 2191-4	5.1	4
92	Virological and immunological outcomes of elvitegravir-based regimen in a treatment-naïve HIV-2-infected patient. <i>Aids</i> , <b>2014</b> , 28, 2329-31	3.5	5
91	Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 2470-6	5.1	16
90	Human Immunodeficiency Viruses Types 1 and 2. <b>2014</b> , 1001-1062		
89	[Infections due to human immunodeficiency virus type 2 and human T-lymphotropic viruses in Spain]. <b>2014</b> , 142, 323-6		2
88	Human immunodeficiency virus type 2 infections in Austria. <b>2014</b> , 126, 212-6		2
87	Novel inhibitors of human immunodeficiency virus type 2 infectivity. <b>2014</b> , 95, 2778-2783		21

86	Reference panel of cloned HIV-2 plasmid DNA for nucleic acid assay development, evaluation, and quality monitoring. <b>2014</b> , 61, 293-7		3
85	New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA load. <i>Journal of Clinical Microbiology</i> , <b>2014</b> , 52, 3017-22	9.7	19
84	Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. <i>Antiviral Research</i> , <b>2014</b> , 102, 70-86	10.8	79
83	The discovery and development of antiretroviral agents. <i>Antiviral Therapy</i> , <b>2014</b> , 19 Suppl 3, 5-14	1.6	18
82	Interobserver variation of the rapid test SD bioline HIV-1/2 3.0 for HIV type discrimination: experiences from Guinea-Bissau. <b>2015</b> , 68, e23-5		12
81	Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System. <b>2015</b> , 7, 6152-62		11
80	Animal and human mucosal tissue models to study HIV biomedical interventions: can we predict success?. <i>Journal of the International AIDS Society</i> , <b>2015</b> , 18, 20301	5.4	8
79	Design, synthesis of new Ecarboline derivatives and their selective anti-HIV-2 activity. <b>2015</b> , 25, 1232-5		36
78	Cohort Profile: The Bissau HIV Cohort-a cohort of HIV-1, HIV-2 and co-infected patients. <b>2015</b> , 44, 756-63		39
77	High level of HIV-1 drug resistance among patients with HIV-1 and HIV-1/2 dual infections in Guinea-Bissau. <b>2015</b> , 12, 41		18
76	Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase. <b>2015</b> , 6, 753-7		34
75	Differential regulatory activities of viral protein X for anti-viral efficacy of nucleos(t)ide reverse transcriptase inhibitors in monocyte-derived macrophages and activated CD4(+) T cells. <i>Virology</i> , <b>2015</b> , 485, 313-21	3.6	5
74	Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239. <i>Journal of Virology</i> , <b>2015</b> , 89, 12002-13	6.6	6
73	The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 7437-46	5.9	10
72	Immunologic response in treatment-naïve HIV-2-infected patients: the leDEA West Africa cohort. <i>Journal of the International AIDS Society</i> , <b>2016</b> , 19, 20044	5.4	12
71	Animal Models for HIV Cure Research. <i>Frontiers in Immunology</i> , <b>2016</b> , 7, 12	8.4	59
70	HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. <i>Microbiology and Molecular Biology Reviews</i> , <b>2016</b> , 80, 679-731	13.2	43
69	Effect of sex and age on outcomes among HIV-2-infected patients starting antiretroviral therapy in West Africa. <i>Aids</i> , <b>2016</b> , 30, 2707-2714	3.5	15

68	A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support. <i>Retrovirology</i> , <b>2016</b> , 13, 85	3.6	8
67	Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors. <i>Aids</i> , <b>2016</b> , 30, 1691-701	3.5	10
66	Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors. <i>Journal of Virology</i> , <b>2016</b> , 90, 1062-9	6.6	20
65	A new vinyl selenone-based domino approach to spirocyclopropyl oxindoles endowed with anti-HIV RT activity. <i>Organic and Biomolecular Chemistry</i> , <b>2016</b> , 14, 2015-24	3.9	44
64	SAMHD1 enhances nucleoside-analogue efficacy against HIV-1 in myeloid cells. <i>Scientific Reports</i> , <b>2017</b> , 7, 42824	4.9	15
63	Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR. <i>Bioorganic and Medicinal Chemistry</i> , <b>2017</b> , 25, 2491-2497	3.4	21
62	Tackling HIV and AIDS: contributions by non-human primate models. <i>Lab Animal</i> , <b>2017</b> , 46, 259-270	0.4	16
61	A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent , , and Antiviral Activity. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	41
60	Physiological Mg Conditions Significantly Alter the Inhibition of HIV-1 and HIV-2 Reverse Transcriptases by Nucleoside and Non-Nucleoside Inhibitors in Vitro. <i>Biochemistry</i> , <b>2017</b> , 56, 33-46	3.2	6
59	New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification. <i>Journal of Clinical Microbiology</i> , <b>2017</b> , 55, 2850-2857	9.7	9
58	A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	27
57	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 2869-2878	5.1	11
56	Animal Models of Human Viral Diseases. <b>2017</b> , 853-901		4
55	A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 1588-1594	11.6	20
54	The challenge of discriminating between HIV-1, HIV-2 and HIV-1/2 dual infections. <i>HIV Medicine</i> , <b>2018</b> , 19, 403-410	2.7	15
53	Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus. <i>Journal of Biological Chemistry</i> , <b>2018</b> , 293, 5323-5334	5.4	22
52	First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2). <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 1161-1167	11.6	19
51	HIV-2 in the United States: rare but not forgotten. <i>Aids</i> , <b>2018</b> , 32, 1547-1549	3.5	1



50	Potent suppression of HIV-1 cell attachment by Kudzu root extract. <i>Retrovirology</i> , <b>2018</b> , 15, 64	3.6	14
49	90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e390-e399	7.8	33
48	Antiviral Activity of Cabotegravir against HIV-2. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	8
47	HIV-2 Infection: Latest Advances. <i>Current Treatment Options in Infectious Diseases</i> , <b>2019</b> , 11, 233-242	1	
46	A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	9
45	Partial Sequences from Drug Naive HIV-2 Infected Individuals from Maharashtra, India. <i>AIDS Research and Human Retroviruses</i> , <b>2019</b> , 35, 505-508	1.6	3
44	Discriminatory rapid tests cause HIV-type misclassification-evaluation of three rapid tests using clinical samples from Guinea-Bissau. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , <b>2019</b> ,	2	1
43	Novel Protease Inhibitors Containing C-5-Modified -Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2RLigands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	8
42	Population-level mathematical modeling of antimicrobial resistance: a systematic review. <i>BMC Medicine</i> , <b>2019</b> , 17, 81	11.4	23
41	Is it time to revise the notion that HIV-2 is benign?. <i>Lancet HIV,the</i> , <b>2018</b> ,	7.8	2
40	InVitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2. <i>Antiviral Research</i> , <b>2019</b> , 161, 85-89	10.8	2
39	Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species. <i>Xenobiotica</i> , <b>2019</b> , 49, 1192-1201	2	18
38	A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 657-667	11.6	15
37	Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa. <i>PLoS ONE</i> , <b>2020</b> , 15, e0236642	3.7	
36	Case 27-2020: A 53-Year-Old Woman with Headache and Gait Imbalance. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 859-866	59.2	
35	Long-term immunological responses to treatment among HIV-2 patients in Cte d'Ivoire. <i>BMC Infectious Diseases</i> , <b>2020</b> , 20, 213	4	
34	Modulation of Cervicovaginal Drug Transporters and Tissue Distribution by Film-Released Tenofovir and Darunavir for Topical Prevention of HIV-1. <i>Molecular Pharmaceutics</i> , <b>2020</b> , 17, 852-864	5.6	3
33	Concerted hydrolysis mechanism of HIV-1 natural substrate against subtypes B and C-SA PR: insight through molecular dynamics and hybrid QM/MM studies. <i>Physical Chemistry Chemical Physics</i> , <b>2020</b> , 22, 2530-2539	3.6	7

32	HIV treatment in Guinea-Bissau: room for improvement and time for new treatment options. <i>AIDS Research and Therapy</i> , <b>2020</b> , 17, 3	3	1
31	Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage. <i>International Journal of Antimicrobial Agents</i> , <b>2020</b> , 55, 105964	14.3	7
30	Human Immunodeficiency Virus-2 (HIV-2): A Summary of the Present Standard of Care and Treatment Options for Individuals Living with HIV-2 in Western Europe. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, 503-509	11.6	5
29	Long-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, 369-378	11.6	6
28	Spiro-lactam BSS-730A Displays Potent Activity against HIV and Plasmodium. <i>ACS Infectious Diseases</i> , <b>2021</b> , 7, 421-434	5.5	5
27	Animal models of HIV transmission through breastfeeding and pediatric HIV infection. <i>Advances in Experimental Medicine and Biology</i> , <b>2012</b> , 743, 89-108	3.6	5
26	HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen. <i>PLoS ONE</i> , <b>2014</b> , 9, e92747	3.7	17
25	Temporal trends in treatment outcomes for HIV-1 and HIV-2-infected adults enrolled in Côte d'Ivoire's national antiretroviral therapy program. <i>PLoS ONE</i> , <b>2014</b> , 9, e98183	3.7	19
24	Interferon alpha antagonizes the anti-hepatoma activity of the oncolytic virus M1 by stimulating anti-viral immunity. <i>Oncotarget</i> , <b>2017</b> , 8, 24694-24705	3.3	9
23	Human Immunodeficiency Virus Type 2: The Neglected Threat. <i>Pathogens</i> , <b>2021</b> , 10,	4.5	1
22	Chapter 15:Development of Anti-HIV Drugs. <i>RSC Biomolecular Sciences</i> , <b>2010</b> , 291-318		
21	HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance. <i>Clinical Drug Investigation</i> , <b>2011</b> , 1	3.2	
20	Structure-Activity Relationship Study of PD 404182 Derivatives for the Highly Potent Anti-HIV Agents. <i>Springer Theses</i> , <b>2013</b> , 41-127	0.1	
19	PROTEASE INHIBITORS: A REVIEW. <i>Indian Drugs</i> , <b>2013</b> , 50, 5-19	0.2	
18	Inhibitors of the Human Immunodeficiency Virus Protease. 113-135		
17	Epidemiology and Prevention of Acquired Immunodeficiency Syndrome and Human Immunodeficiency Virus Infection. <b>2015</b> , 1483-1502.e8		
16	Comparison of HIV-1, SIV-1, and SHIV in Protein Translation Using Apriori Algorithm. <i>Journal of Medical and Bioengineering</i> , <b>2015</b> , 4, 130-134		1
15	Emergence of HIV Types and Risk Factors in Pregnant Women in Burkina Faso from 2006 to 2014. <i>Journal of Microbiology &amp; Experimentation</i> , <b>2017</b> , 5,	0.2	

14	Low Level of HIV-2 Replication in Patients on Long-Term Antiretroviral Therapy in Togo. <i>Journal of Microbiology &amp; Experimentation</i> , <b>2017</b> , 5,	0.2	
13	Encyclopedia of AIDS. <b>2018</b> , 88-95		
12	HIV-Associated Nephropathy in an HIV-2-Infected Patient. <i>World Journal of AIDS</i> , <b>2020</b> , 10, 15-22	0.3	
11	HIV Reservoirs: Modeling, Quantification, and Approaches to a Cure.. <i>Methods in Molecular Biology</i> , <b>2022</b> , 2407, 215-228	1.4	
10	British HIV Association guidelines for the management of HIV-2 2021.. <i>HIV Medicine</i> , <b>2021</b> , 22 Suppl 4, 1-29	2.7	1
9	Novel assays to investigate the mechanisms of latent infection with HIV-2.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0267402	0.7	
8	Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 829-848	1.6	73
7	In vitro Phenotypic Susceptibility to Nucleoside Reverse Transcriptase Inhibitors of HIV-2 Isolates with the Q151M Mutation in the Reverse Transcriptase Gene. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 861-865	1.6	15
6	Antiretroviral Drug Resistance in Non-Subtype B HIV-1, HIV-2 and Siv. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 3-12	1.6	37
5	Polymorphisms, Resistance and Drug Response: Beyond Subtype-B HIV-1. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 1-1	1.6	
4	Can in-house HIV-2 viral load assay be a reliable alternative to commercial assays for clinical and therapeutic monitoring?. <i>Current HIV Research</i> , <b>2022</b> , 20,	1.3	
3	High Instantaneous Inhibitory Potential of Bictegravir and the New Spiro-Lactam BSS-730A for HIV-2 Isolates from RAL-Naïve and RAL-Failing Patients. <b>2022</b> , 23, 14300		1
2	Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds. <b>2023</b> , 24, 5905		0
1	The Humanized Mouse Model: What Added Value Does It Offer for HIV Research?. <b>2023</b> , 12, 608		0